Understand the source comparison
Peptides for Dementia Prevention — Comparison Evidence
Cerebrolysin BDNF/NGF receptor agonism, neurotrophic support 20+ RCTs in AD and VaD populations; Phase III complete Intravenous only 30mL IV daily × 20 days Most robust evidence base; modest effect size; requires clinical administration Dihexa HGF/c-Met activa
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- BDNF/NGF receptor agonism, neurotrophic support
- 20+ RCTs in AD and VaD populations; Phase III complete
- Intravenous only
- 30mL IV daily × 20 days
- Most robust evidence base; modest effect size; requires clinical administration
- Dihexa
- HGF/c-Met activation, synaptogenesis
- None. Preclinical only
- Oral or subcutaneous (animal models)
- Unknown. No human PK data
- Potent in rodent models; zero human safety data; purely investigational
- P21
- TrkB receptor activation, hippocampal neurogenesis
- Intranasal (animal models)
- 1–5mg intranasal (extrapolated)
- Neurogenic in aged mice; no human dosing protocol; experimental
- Thymalin
- Thymic peptide, immune modulation
- Limited Eastern European trials
- Subcutaneous
- 10–30mg × 10 days
- Immune-focused; indirect neuroprotection hypothesis; minimal dementia-specific data
- Cerebrolysin is the only compound here with reproducible human efficacy data—but the effect size is small, and IV administration limits accessibility. Dihexa and P21 show compelling preclinical promise but remain unproven and potentially unsafe in humans without formal toxicology studies.